Abstracts tagged "Cohort Study"

Abstract Number: 0300 • ACR Convergence 2025
Exploring Malignancy in Anti-synthetase Syndrome: A Multisite Retrospective Study
Reena Yaman¹, Archit Srivastava², Alejandro Arango Martinez³, Caroyln Harvey⁴, Ronald Butendieck⁵, Vikas Majithia⁶ and Florentina Berianu¹, ¹Mayo Clinic Florida, Jacksonville, FL, ²Mayo Clinic, Florida, Jacksonville, FL, ³Universidad Pontificia Bolivariana, Medellín, Colombia, ⁴Mayo Clinic, Phoenix, AZ, ⁵Mayo Clinic Florida, Jacksonville, ⁶Mayo Clinic Hospital, Jacksonville, FL
Background/Purpose: Anti-synthetase syndrome (ASyS) is a rare, heterogeneous inflammatory myopathy characterized by presence of anti-aminoacyl transfer RNA synthetase autoantibodies with multisystem disease manifestations including myositis,…
Abstract Number: 2503 • ACR Convergence 2025
Validation of a Composite Biomarker Score To Predict Modified Rodnan Skin Score: Insight From Autologous Stem Cell Transplantation International Scleroderma trial
stefano rodolfi¹, kristina clark², bahja Ahmed Abdi¹, medha kanitkar³, Voon H. Ong³, Alexandre Voskuijl⁴, Jeska de Vries-Bouwstra⁵, Jacob M. van Laar⁶, Christopher Denton⁷ and julia Spierings⁸, ¹University College London, London, United Kingdom, ²Kennedy Institute of Rheumatology, University of Oxford, London, United Kingdom, ³Division of Medicine, Centre for Rheumatology, University College London, London, United Kingdom, ⁴Amsterdam University Medical Center, Amsterdam, Netherlands, ⁵Leiden University Medical Center, Leiden, Netherlands, ⁶UMC Utrecht, Utrecht, Netherlands, ⁷University College London, UK, London, United Kingdom, ⁸Department of Rheumatology & Clinical Immunology, University Medical Center, Ultrecht, The Netherlands, Utrecht, Netherlands
Background/Purpose: Skin fibrosis is a cardinal manifestation of diffuse cutaneous systemic sclerosis (dcSSc) and is routinely measured via the modified Rodnan skin score (mRSS); however,…
Abstract Number: 2302 • ACR Convergence 2025
Clustering by ESSPRI and PROMIS domain measures defines distinct subtypes and facilitates longitudinal assessment of patients with Sjogren’s disease
Thomas Grader-Beck¹, Jennifer Reed², Priya Patel³, Ji Soo Kim⁴ and Alan Baer⁵, ¹Johns Hopkins, Reisterstown, MD, ²Johns Hopkins, Freeland, MD, ³Johns Hopkins, Annville, PA, ⁴Johns Hopkins, Baltimore, MD, ⁵Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Patient-reported outcomes (PROs) measure a patient’s health-related quality of life. The role of ESSPRI and PROMIS measures in identifying subsets of patients with Sjogren’s…
Abstract Number: 2028 • ACR Convergence 2025
Behçet’s Syndrome Beyond Endemic Borders: A 24-Year Longitudinal Analysis of Mortality in a Diverse South American Cohort
Fabio Specian¹, Carolina Ejnisman², Rafael Bassara Macedo¹, Pedro Araujo³, Barbara Bayeh², Thiago Freitas⁴, Rafael Cordeiro⁵ and Henrique Giardini⁴, ¹Rheumatology Division, Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo (USP), Sao Paulo, Sao Paulo, Brazil, ²Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, Brazil, ³Universidade de São Paulo, Sao Paulo, São Paulo, Brazil, ⁴Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, Brazil, ⁵Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, Sao Paulo, Brazil
Background/Purpose: Behçet’s syndrome (BS) is a chronic, relapsing vasculitis that contributes substantially to morbidity and mortality, primarily due to vascular and neurological complications. Most of…
Abstract Number: 1670 • ACR Convergence 2025
Large Retrospective Cohort Study Of Chronic Recurrent Multifocal Osteomyelitis: Disease Presentation, Clinical, And Laboratory Features
Shima Yasin¹, Shima Yasin² and Polly Ferguson³, ¹King Abdullah Specialized Children’s Hospital,Ministry of National Guard Health Affairs, Jeddah, Saudi Arabia, ²Univeristy of Iowa, Iowa City, ³University of Iowa Carver College of Medicine, Iowa City, IA
Background/Purpose: Chronic recurrent multifocal osteomyelitis (CRMO) is an autoinflammatory bone disease that affects children and adolescents. The disease typically presents with bone pain with or…
Abstract Number: 1489 • ACR Convergence 2025
Impact of Menopause on Long-Term Outcomes in Patients with Systemic Lupus Erythematosus
Lorena López, José Bretón and Luis Vilá, University of Puerto Rico Medical Sciences Campus, San Juan, PR
Background/Purpose: Women of childbearing age are more prone to developing autoimmune diseases, suggesting a role for sex hormones, particularly estrogens, in regulating both cellular and…
Abstract Number: 1173 • ACR Convergence 2025
Prevalence of Coronary Artery Involvement in IgG4-Related Disease Detected by Non-Gated Cross-Sectional Imaging
Matthew Charles Baker¹, Lauren Taylor², Haziq Siddiqi², Jison Hong² and Brian Pogatchnik², ¹Stanford University, Menlo Park, CA, ²Stanford University, Stanford, CA
Background/Purpose: IgG4-related disease (IgG4-RD) classically presents with a mass or diffusely enlarged organ, but it also affects blood vessels of all sizes. Coronary artery involvement…
Abstract Number: 0659 • ACR Convergence 2025
Human papillomavirus infection and systemic lupus erythematosus under biologic therapy: a retrospective analysis in a multicenter cohort
Ivette Casafont-Solé¹, Judit Font-Urgelles¹, Iñigo Rúa-Figueroa², Andrea Hernández-martín³, Tarek Salman Montes⁴, Marta De la Rubia Navarro⁵, Maria Piqueras García⁶, Sandra Garrote Corral⁷, EVA GLORIA TOMERO MURIEL⁸, Elena De la Mata Pinilla⁹, Belén Álvarez Rodríguez¹⁰, Julia Martínez Barrio¹¹, José Gomez-Puerta¹², Paola Vidal-Montal¹³, Eleonora Penzo¹⁴, Consuelo Ramos Giraldez¹⁵, Francisco Javier Novoa¹⁶, Vicenç Torrente-Segarra¹⁷, Jorge Juan Fragío Gil¹⁸, Leyre Riancho¹⁹ and Irene Altabás-González²⁰, ¹Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ²Hospital de Gran Canaria Doctor Negrin, Las Palmas GC, Spain, ³Hospital Universitario de Gran Canaria Dr Negrín, Las palmas, Spain, ⁴Hospital del Mar/Parc de Salut Mar-IMIM, Barcelona, Spain, ⁵Hospital de La Fe, Valencia, ⁶Servicio Murciano de Salud, Murcia, Spain, ⁷Hospital Ramón y Cajal, Madrid, ⁸Hospital Universitario de la Princesa, Madrid, Spain, ⁹Hospital ¹² de Octubre, Madrid, ¹⁰Hospital de Áraba, áraba, Spain, ¹¹Department of Rheumatology, Hospital Gregorio Marañón, Madrid, Spain, Madrid, Madrid, Spain, ¹²Rheumatology Department, Hospital Clinic, Barcelona, Spain, Barcelona, Spain, ¹³Rheumatology. Hospital Universitari de Bellvitge, Barcelona, Catalonia, Spain, ¹⁴Hospital Vall d'Hebrón, Barcelona, Spain, ¹⁵Hospital Universitario Virgen de Valme, Servicio de Reumatología, Seville, Spain, ¹⁶Hospital Insular de Gran Canaria, Las palmas, ¹⁷Hospital Comarcal Alt Penedés Garraf, Vilafranca del Penedès, Spain, ¹⁸Hospital General Universitario, Valencia, Spain, ¹⁹Hospital de Sierrallana, Torrelavega, ²⁰Complejo Hospitalario de Vigo, Vigo, Spain
Background/Purpose: Human papillomavirus (HPV) is responsible for 99.7% of cervical neoplasms and is the fourth most common cancer among women worldwide. Patients with systemic lupus…
Abstract Number: 0517 • ACR Convergence 2025
Gut Microbiota Dysbiosis and Clinical Predictors of Fatigue in Primary Sjögren’s Syndrome: A Multi-Omics Study
Qiguo Cui¹, Pan Wang², Bin Zhou¹ and QIn Huang³, ¹Southern Medical Univercity Nanfang Hospital, guang zhou, China (People's Republic), ²southern medical university Nanfang Hospital, Guangzhou, China (People's Republic), ³Nanfang Hospital, Guangzhou, China (People's Republic)
Background/Purpose: Fatigue affects 70% of primary Sjögren's syndrome (pSS) patients, but its mechanisms remain unclear. We investigated clinical predictors and gut microbiota associations in pSS-related…
Abstract Number: 0299 • ACR Convergence 2025
Interpreting Myositis Autoantibody Line-Blot Immunoassays in Real-World Settings: Implications for Diagnostic Accuracy for Inflammatory Myopathies
pei-Hsinq lai¹, TING-YUAN LAN², Chiao-Feng Cheng³, Tai-Ju Lee⁴, Ting-Wei Chang⁵, Jui-Hung Kao⁶, Kuan-Yen Lin⁷, Cheng-Hsun Lu⁸, Chiehyu Shen⁹, Ko-Jen Li⁸ and Song-Chou Hsieh¹⁰, ¹Taipei City Hospital, Taichung, Taiwan, ²National Taiwan University Hospital Hsinchu Branch, Hsinchu City, Taiwan, ³National Taiwan University Hospital, Taipei City, Taiwan (Republic of China), ⁴National Taiwan University Hospital Hsinchu Branch, Hsinchu City, Taiwan (Republic of China), ⁵National Taiwan University Hospital Hsinchu Branch, Taichung, Taiwan, ⁶Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan, Taipei, Taiwan (Republic of China), ⁷National Taiwan University Hospital, Hsin-Chu Branch, Hsin-Chu City, Taiwan (Republic of China), ⁸National Taiwan University Hospital, Taipei, Taiwan, ⁹National Taiwan University Hospital, Taipei city, Taiwan, ¹⁰National Taiwan Unuversity Hospital, Taipei City, Taiwan (Republic of China)
Background/Purpose: Idiopathic inflammatory myopathies (IIM) present with diverse clinical features and disease courses. The myositis autoantibody line blot immunoassay (LIA) has advanced IIM diagnostics and…
Abstract Number: 2496 • ACR Convergence 2025
Comparing Long-term Outcome Across Systemic Sclerosis Subgroups Using a Multi-Organ Disease Progression Score
Philip Yee¹, medha kanitkar², stefano rodolfi³, Voon H. Ong² and Christopher Denton⁴, ¹Division of Medicine, Centre for Rheumatology, University College London, London, England, United Kingdom, ²Division of Medicine, Centre for Rheumatology, University College London, London, United Kingdom, ³University College London, London, United Kingdom, ⁴University College London, UK, London, United Kingdom
Background/Purpose: Evaluating disease modification in systemic sclerosis (SSc) is challenging and requires long term studies. This is especially relevant to limited cutaneous (lc)SSc where severe…
Abstract Number: 2245 • ACR Convergence 2025
Add-on of Coronary Artery Calcium Score Significantly Improves the Risk Prediction of Cardiovascular Diseases in Patients with Rheumatoid Arthritis: From a Real-world Cohort Study
Yao-Wei Zou, Ying Yang, Zhi-Ming Ouyang, Ran Shi, Tao Wu, Kui-Min Yang, Jian-Da Ma and Lie Dai, Department of Rheumatology and Immunology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China (People's Republic)
Background/Purpose: Cardiovascular diseases (CVD) are the first cause of death in patients with rheumatoid arthritis (RA). The guidelines recommend risk prediction in all RA patients.…
Abstract Number: 2023 • ACR Convergence 2025
Isolated Anti-Ro52 Antibody Positivity Is Associated with Increased Cancer Risk and Distinct Malignancy Patterns: A Retrospective Cohort Study from a Single Tertiary Center
Carmen Secada-Gómez¹, Ligia Gabrie-Rodriguez², Hector Ulloa-Alvarado³, Giuliano Boselli⁴, Camilo Veloza-Morales⁵, Diana Prieto-Peña⁶, juan Irure-Ventura⁷, Marcos López-Hoyos⁸ and Ricardo Blanco¹, ¹Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain, ²Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ³Servicio Cántabro de Salud, Atención Primaria, Santander, Spain, Santander, Cantabria, Spain, ⁴Rheumatology Division, Hospital Universitario Miguel Servet , Zaragoza, Spain, Zaragoza, Aragon, Spain, ⁵Rheumatology Division, Hospital Universitario Joan XXIII, Tarragona, Spain, Tarragona, Catalonia, Spain, ⁶Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Santander, Spain, ⁷Division of Immunology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Cantabria, Spain, ⁸Division of Immunology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain
Background/Purpose: Anti-Ro52 antibodies are frequently detected in patients with systemic autoimmune rheumatic diseases (SARDs). Emerging evidence suggests a potential link between isolated anti-Ro52 positivity and…
Abstract Number: 1665 • ACR Convergence 2025
Comparative Effectiveness of Biologic Versus Conventional Therapy in Uveitis with Systemic Rheumatic Diseases: Real-World Evidence from a Propensity-Matched Cohort
Hanieh Akbari¹ and shahrzad Abdollahi², ¹Jefferson Einstein Montgomery Medical Center, Norristown, PA, ²Jefferson Einstein Philadelpha, Philadelphia, PA
Background/Purpose: Uveitis is a vision-threatening manifestation of systemic rheumatic diseases. While conventional immunosuppressants are typically first-line, biologics are often reserved for refractory cases. Long-term real-world…
Abstract Number: 1486 • ACR Convergence 2025
Systemic Lupus Erythematosus and Statins in GLADEL 2.0: Are Cardiovascular Risk Prevention Guidelines Being Followed?
Ileana C. Reynosa-Silva¹, Iris J. Colunga-Pedraza², Guillermina Harvey³, Dionicio A. Galarza-Delgado², Jose R Azpiri-Lopez⁴, Fernanda M. Garcia-Garcia², Oscar Azael Garza-Flores⁵, Marina Scolnik⁶, Gisela Subils⁷, CINTIA OTADUY⁸, Veronica Saurit⁹, Valeria Arturi¹⁰, Leonel Berbotto¹¹, Guillermo Pons-Estel¹², Luciana Gonzalez Lucero¹³, Melissa Brenda Serna Góngora¹⁴, Maria de los Angeles Gargiulo¹⁵, Cecilia Pisoni¹⁶, Maria Elena Crespo¹⁷, Mónica Sánchez Guamán¹⁸, Vitalina de Souza Barbosa¹⁹, Andrese Aline Gasparin²⁰, Henrique Ataide Mariz²¹, Francinne Ribeiro²², Eduardo Borba²³, Edgard dos Reis-Neto²⁴, Iris Guerra Herrera²⁵, Maria Loreto Massardo²⁶, Gustavo Aroca Martínez²⁷, Carlos Alberto Cañas²⁸, Gerardo Quintana-Lopez²⁹, Carlos Toro-Gutierrez³⁰, Mario Moreno Alvarez³¹, MIGUEL SAAVEDRA³², Margarita Portela Hernández³³, Hilda Fragoso-Loyo³⁴, Luis M Amezcua-Guerra³⁵, Ignacio García-De la Torre³⁶, Jorge Isaac Velasco Santos³⁷, Jorge Antonio Esquivel Valerio³⁸, Jhonatan Losanto³⁹, Magaly Alva Linares⁴⁰, Manuel Ugarte-Gil⁴¹, Katiuzka Zuñiga Corrales⁴², Roberto Muñoz-Louis⁴³, Carina Pizzarossa⁴⁴, Gonzalo Silveira⁴⁵, Federico Zazzetti⁴⁶, Ashley Orillion⁴⁷ and Gloria Vásquez⁴⁸, ¹Rheumatology Service, Hospital Universitario “Dr. Jose Eleuterio Gonzalez”, Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ²Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico, ³Universidad Nacional de Rosario, Rosario, Argentina, Rosario, Argentina, ⁴Cardiology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico, ⁵Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Guadalupe, Mexico, ⁶Hospital Italiano de Buenos Aires, Argentina, Buenos Aires, Argentina, ⁷Hospital Italiano de Córdoba, Córdoba, Argentina, Córdoba, Argentina, ⁸Servicio de Reumatología Hospital Córdoba y Sanatorio Allende, Facultad de Ciencias Médicas, Universidad Nacional de Córdoba, Córdoba, Argentina, Córdoba, Argentina, ⁹Hospital Privado Universitario de Cordoba, Córdoba, Argentina, Córdoba, Argentina, ¹⁰Hospital San Martin de La Plata, La Plata, Argentina, La Plata, Argentina, ¹¹Sanatorio Británico; Rosario, Argentina, Rosario, Argentina, ¹²Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR); Rosario, Argentina, Rosario, Argentina, ¹³Hospital Ángel C. Padilla, Tucumán, Argentina, Tucumán, Argentina, ¹⁴Hospital J.M Ramos Mejía, Buenos Aires, Argentina;, Buenos Aires, Argentina, ¹⁵Instituto de Investigaciones Médicas Alfredo Lanari, Universidad de Buenos Aires; Buenos Aires, Argentina, Buenos Aires, Argentina, ¹⁶CEMIC Centro de Educación Médica e Investigaciones Clínicas ‘‘Norberto Quirno”, Buenos Aires, Argentina, Ciudad Autonoma Buenos Aires, Argentina, ¹⁷Hospital Señor del Milagro Salta, Salta, Argentina, Salta, Argentina, ¹⁸Hospital General de Agudos Dr. Juan A. Fernández, Buenos Aires, Argentina, Buenos Aires, Argentina, ¹⁹Hospital das Clinicas da Universidade Federal de Goias, Goiania, Brazil, Goiania, Brazil, ²⁰Hospital de Clínicas de Porto Alegre, Universidade Federal Do Rio Grande Do Sul, Porto Alegre, Brazil, Porto Alegre, Brazil, ²¹Universidad Federal de Pernambuco, Recife, Brazil, Recife, Brazil, ²²Hospital Universitário Pedro Ernesto - Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, Rio De Janeiro, Rio de Janeiro, Brazil, ²³Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, São Paulo, Brazil, ²⁴Escola Paulista de Medicina / Universidade federal de São Paulo (EPM / Unifesp), São Paulo, Brazil, São Paulo, Brazil, ²⁵Hospital del Salvador Santiago de Chile, Santiago, Chile, Santiago, Chile, ²⁶Facultad de Medicina y Ciencia, Universidad San Sebastián, Santiago, Chile, Santiago, Chile, ²⁷Universidad Simón Bolívar, Barranquilla, Colombia y Clínica de la Costa, Barranquilla, Colombia, ²⁸Fundación Valle del Lili, Universidad Icesi, Cali, Colombia, Cali, Colombia, ²⁹Facultad de Medicina, Universidad Nacional de Colombia; Hospital Universitario Fundación Santa Fe de Bogotá; Hospital Universitario Nacional de Colombia, Bogotá, Colombia, Bogotá, Colombia, ³⁰Pontificia Universidad Javeriana de Cali, Cali, Colombia, Cali, Colombia, ³¹Universidad de Especialidades Espíritu Santo, Guayaquil, Ecuador, Guayaquil, Ecuador, ³²Hospital de Especialidades Dr. Antonio Fraga Mouret, Centro Médico Nacional La Raza, Instituto Mexicano del Seguro Social, Mexico City, Mexico, MEXICO, Mexico, ³³Hospital de Especialidades del Centro Médico Nacional SXXI, Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico, Mexico City, Mexico, ³⁴Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, Mexico City, Mexico, ³⁵Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico, Mexico city, ³⁶Centro de Estudios de Investigación Básica y Clínica, S.C., Guadalajara, Mexico, Guadalajara, Jalisco, Mexico, ³⁷Facultad de Medicina de la Universidad Autónoma de San Luis Potosí y Hospital Central "Dr. Ignacio Morones Prieto, " San Luis Potosí, Mexico, San Luis Potosí, Mexico, ³⁸Universidad Autónoma de Nuevo León, Rheumatology Service, Hospital Universitario "Dr. José Eleuterio González", Monterrey, Nuevo León, México., MONTERREY, Mexico, ³⁹Facultad de Ciencias Medicas, Universidad Nacional de Asunción, San Lorenzo, Paraguay, San Lorenzo, Paraguay, ⁴⁰Hospital Nacional Edgardo Rebagliati Martins-EsSalud, Lima, Peru, Lima, Peru, ⁴¹Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas, Universidad Científica del Sur, Lima, Peru; Hospital Guillermo Almenara Irigoyen, EsSalud, Lima, Peru, Lima, Peru, ⁴²Hospital Nacional Cayetano Heredia, Universidad Peruana Cayetano Heredia, San Martín de Porres, Peru, San Martín de Porres, Peru, ⁴³Hospital Docente Padre Billini, Santo Domingo, Distrito Nacional, Dominican Republic, ⁴⁴Hospital de Clínicas, Facultad de Medicina, UDELAR, Montevideo, Uruguay, Montevideo, Uruguay, ⁴⁵Facultad de Medicina - Universidad de la República, Montevideo, Uruguay, Montevideo, Uruguay, ⁴⁶Johnson & Johnson, Horsham, PA, USA, Ambler, PA, ⁴⁷Johnson & Johnson, Spring House, PA, USA, Spring House, PA, ⁴⁸Sede de Investigación Universitaria (SIU), Universidad de Antioquia (UDEA), Medellín, Colombia., Medellín, Colombia
Background/Purpose: Patients (pts) with systemic lupus erythematosus (SLE) have a significantly increased risk of atherosclerotic cardiovascular disease (ASCVD). EULAR recommends a comprehensive assessment and management…

« Previous Page
1
…
4
5
6
7
8
…
38
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].